Cypress Capital Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.8M Buy
79,197
+3,643
+5% +$212K 0.54% 50
2025
Q4
$4.08M Buy
75,554
+2,193
+3% +$105K 0.46% 51
2025
Q3
$3.31M Sell
73,361
-478
-0.6% -$22.3K 0.4% 62
2025
Q2
$3.42M Buy
73,839
+1,570
+2% +$77.1K 0.43% 56
2025
Q1
$4.41M Buy
72,269
+2,743
+4% +$160K 0.58% 48
2024
Q4
$3.93M Sell
69,526
-5,350
-7% -$299K 0.48% 53
2024
Q3
$3.87M Sell
74,876
-24,205
-24% -$1.14M 0.44% 57
2024
Q2
$4.11M Sell
99,081
-1,912
-2% -$85.6K 0.49% 53
2024
Q1
$5.48M Buy
100,993
+1,745
+2% +$88.9K 0.66% 41
2023
Q4
$5.09M Buy
99,248
+1,126
+1% +$59.1K 0.66% 42
2023
Q3
$5.69M Sell
98,122
-1,374
-1% -$84.2K 0.82% 30
2023
Q2
$6.36M Sell
99,496
-9,805
-9% -$657K 0.92% 28
2023
Q1
$7.58M Sell
109,301
-8,367
-7% -$590K 1.16% 18
2022
Q4
$8.47M Buy
117,668
+2,756
+2% +$208K 1.28% 16
2022
Q3
$8.17M Buy
114,912
+6,747
+6% +$489K 1.36% 12
2022
Q2
$8.33M Sell
108,165
-934
-0.9% -$71.1K 1.27% 16
2022
Q1
$7.97M Buy
109,099
+9,759
+10% +$655K 0.98% 26
2021
Q4
$6.19M Buy
99,340
+7,604
+8% +$446K 0.78% 37
2021
Q3
$5.43M Sell
91,736
-1,344
-1% -$88.5K 0.74% 37
2021
Q2
$6.22M Sell
93,080
-5,353
-5% -$349K 0.84% 31
2021
Q1
$6.21M Sell
98,433
-13,289
-12% -$827K 0.88% 31
2020
Q4
$6.93M Sell
111,722
-5,307
-5% -$326K 1.04% 30
2020
Q3
$7.05M Buy
117,029
+3,956
+3% +$238K 1.18% 23
2020
Q2
$6.65M Buy
113,073
+6,065
+6% +$363K 1.22% 22
2020
Q1
$5.96M Sell
107,008
-397
-0.4% -$24.3K 1.38% 20
2019
Q4
$6.89M Buy
107,405
+35,304
+49% +$2.02M 1.23% 20
2019
Q3
$3.66M Buy
72,101
+11,764
+19% +$553K 0.7% 45
2019
Q2
$2.74M Buy
60,337
+3,269
+6% +$152K 0.54% 60
2019
Q1
$2.72M Sell
57,068
-2,552
-4% -$127K 0.56% 57
2018
Q4
$3.1M Buy
59,620
+1,944
+3% +$104K 0.71% 45
2018
Q3
$3.58M Sell
57,676
-1,396
-2% -$82.8K 0.68% 52
2018
Q2
$3.27M Sell
59,072
-21,484
-27% -$1.16M 0.67% 50
2018
Q1
$5.09M Buy
80,556
+6,410
+9% +$412K 1.07% 26
2017
Q4
$4.54M Buy
74,146
+4,125
+6% +$258K 0.95% 30
2017
Q3
$4.46M Sell
70,021
-325
-0.5% -$19K 0.95% 29
2017
Q2
$3.92M Sell
70,346
-6,995
-9% -$381K 0.87% 36
2017
Q1
$4.21M Sell
77,341
-4,906
-6% -$269K 0.98% 34
2016
Q4
$4.81M Sell
82,247
-9,693
-11% -$530K 1.14% 27
2016
Q3
$4.96M Sell
91,940
-690
-0.7% -$44.3K 1.18% 27
2016
Q2
$6.81M Sell
92,630
-1,812
-2% -$128K 1.59% 18
2016
Q1
$6.03M Buy
94,442
+87
+0.1% +$5.49K 1.48% 24
2015
Q4
$6.49M Sell
94,355
-16,190
-15% -$1.07M 1.57% 19
2015
Q3
$6.54M Buy
110,545
+2,045
+2% +$130K 1.61% 19
2015
Q2
$7.22M Buy
108,500
+525
+0.5% +$34.6K 1.66% 15
2015
Q1
$6.96M Buy
107,975
+1,062
+1% +$66.5K 1.59% 15
2014
Q4
$6.31M Sell
106,913
-9,436
-8% -$532K 1.46% 19
2014
Q3
$5.95M Sell
116,349
-4,050
-3% -$202K 1.41% 20
2014
Q2
$5.84M Sell
120,399
-942
-0.8% -$46.4K 1.37% 21
2014
Q1
$6.3M Sell
121,341
-9,837
-7% -$523K 1.55% 17
2013
Q4
$6.97M Sell
131,178
-4,990
-4% -$254K 1.71% 14
2013
Q3
$6.3M Sell
136,168
-1,989
-1% -$87.3K 1.56% 15
2013
Q2
$6.17M Buy
+138,157
New +$6M 1.29% 20

Other funds holding BMY

Cypress Capital Group's BMY Position: Q1 2026 in Review

Cypress Capital Group increased its Bristol-Myers Squibb (BMY) stake by 4.8% in Q1 2026, buying an estimated $212K and bringing the position to 79,197 shares worth $4.8M. The position accounts for 0.54% of the portfolio, ranked #50.

Cypress Capital Group first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.47M in Q4 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cypress Capital Group held 79,197 shares of Bristol-Myers Squibb worth $4.8M as of Q1 2026.
  • Cypress Capital Group bought 3,643 Bristol-Myers Squibb shares in Q1 2026, an estimated $212K.
  • Bristol-Myers Squibb made up 0.54% of Cypress Capital Group's portfolio in Q1 2026, its #50 holding.
  • Cypress Capital Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Cypress Capital Group's Bristol-Myers Squibb position peaked at $8.47M in Q4 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cypress Capital Group's 13F filing for Q1 2026, filed 15 May 2026.